Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (Jiang Jingting)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (Jiang Jingting) refers to an investigational second-generation chimeric antigen receptor (CAR) T-cell therapy developed by Jingting Jiang's team at Soochow University. The therapy utilizes allogeneic T-cells engineered with a viral vector to express a CAR targeting the CD19 antigen, which is widely expressed on B-cell malignancies. The CAR construct incorporates a CD28 costimulatory domain and a CD3ζ (TCRζ) signaling domain to enhance T-cell activation and survival. A distinctive feature of this research program is the clinical evaluation of different cytokine expansion protocols—specifically comparing IL-2 pre-treatment against a combination of IL-7 and IL-15—to optimize the safety, expansion, and clinical efficacy of the CAR-T cells in patients with chemotherapy-resistant or refractory CD19+ B-cell lymphoma.
- Other names
- Anti-CD19:TCRζ Chimeric Antigen Receptor-T CellsCD19-CD28-ζ CAR-T cellsIL-2 pre-treated CD19 CAR T-cellsIL2 pre-treated CD19 CAR T-cellsIL 2 pre-treated CD19 CAR T-cellsIL-7/IL-15 pre-treated CD19 CAR T-cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (Jiang Jingting).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (Jiang Jingting).